Clinical Trial Update: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase 2 trial update for ponatinib in chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Ponatinib (ponatinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-01-29